Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Switch to Sarilumab from Adalimumab Is Efficacious and Safe

Switch to Sarilumab from Adalimumab Is Efficacious and Safe

Presented By
Dr Gerd Burmester, Free University and Humboldt University of Berlin, Germany
Conference
EULAR 2019
Trial
MONARCH

Switching from adalimumab to sarilumab improves signs and symptoms in patients with rheumatoid arthritis (RA). The safety profile in the open-label-extension (OLE) study was consistent with that observed in the prior MONARCH study.

In the MONARCH trial, patients who were intolerant or responded inadequately to methotrexate received sarilumab subcutaneously (200 mg twice weekly; n=184) or adalimumab (40 mg twice weekly; n=185) for a total of 24 weeks. The results showed sarilumab monotherapy to be superior compared with adalimumab monotherapy in DAS28-ESR, ACR20/50/70 response, HAQ-DI, and CDAI. Dr Gerd Burmester (Free University and Humboldt University of Berlin, Germany) et al. aimed to assess long-term efficacy and safety in RA patients continuing sarilumab (n=165) or switching from adalimumab to sarilumab monotherapy (n=155) in the OLE follow-up study of MONARCH.

The results showed that, with regard to the primary DAS28-ESR and CDAI endpoints, &g...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on